• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    LifeStance Health Group (LFST) Stock May Be 22% Below Fair Value Following Raised Guidance

    Simply Wall St·09/26/2026 23:23:46
    语音播报

    LifeStance Health Group has seen its stock surge over the past year, and that sharp move now puts the spotlight squarely on whether the current share price lines up with the cash the business can generate over time. With expectations reset by recent results and a stronger share price, the key issue is how those cash flows stack up against where the market is pricing the company today.

    • LifeStance Health Group has returned 118.5% over the past year, which raises the question of how much future cash flow strength is already reflected in the stock.
    • Recent revenue growth and improved profitability may support higher long term cash generation, although investors still need to weigh that against past losses and limited free cash flow margins.
    • Prefer to judge LifeStance Health Group on earnings? See why LifeStance Health Group's 89.4x P/E tells a different valuation story.

    The issue now is whether LifeStance Health Group's current valuation is justified by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

    If you are testing whether LifeStance Health Group's surge still leaves room based on its cash flows, it can help to compare against a curated set of 32 high quality undervalued stocks.

    Is LifeStance Health Group Still Cheap on Cash Flow?

    The Discounted Cash Flow (DCF) approach here looks at the cash that LifeStance Health Group could return to shareholders over time and discounts it back to today. LifeStance is currently generating last twelve month free cash flow of about $178.2 million, and the model assumes that figure grows, with projected annual cash flows rising into the next decade rather than shrinking.

    Those expanding free cash flow forecasts imply that the DCF estimate of intrinsic worth sits meaningfully above the current $11.84 share price. The recent Q2 update, with higher guidance and improved profitability, helps explain why the projections lean on ongoing cash flow strength even though the business has a history of earlier losses and modest free cash flow margins. Because of that mix of stronger recent execution and still cautious long term assumptions on cash generation, the discounted cash flow outcome suggests the market price is not fully reflecting the cash flows implied by the model yet. Find out what LifeStance Health Group could be worth using our Discounted Cash Flow (DCF) estimate.

    The LifeStance Health Group Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where the LifeStance Health Group valuation puzzle leaves off by explaining which paths for growth, margins and earnings would need to occur for the shares to be worth significantly more or less than today’s level. They do this by clearly laying out the assumptions behind each fair value view so you can compare those inputs with LifeStance Health Group's actual results as they are reported on the Community page.

    One of the top community narratives on LifeStance Health Group: 17% undervalued

    "Investments in AI and digital technology platforms are expected to drive operating leverage, reduce administrative costs, and improve clinician productivity…"

    Discover why this Narrative puts LifeStance Health Group at 17% undervalued.

    One more check for LifeStance Health Group before you stop at the share price

    Cash flows and market value tell only part of the story, because the people setting priorities and their pay structure can pull results in very different directions over time. See who runs LifeStance Health Group and how they are paid.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.